Table 1 Demographics and genotypes of participants

Participants (n, %)

51 (48%)

18 (17%)

23 (21%)

3 (3%)

4 (4%)

8 (7%)

Age (year), median [IQR]

44 [39–51]

43 [39–53]

42 [38–45]

42 [41–43]

46 [44–51]

44 [38–50]

Males (n, %)

48 (94%)

15 (83%)

20 (87%)

3 (100%)

4 (100%)

8 (100%)

Body weight (kg), median [IQR]

65 [58–72]

66 [58–72]

67 [61–74]

64 [61–77]

55 [51–59]

68 [60–73]

Treatment naïve (n, %)

9 (18%)

5 (28%)

9 (39%)

0 (0%)

1 (25%)

2 (25%)

CD4 cell count (cells/mL), median at the time of sampling [IQR]

486 [329–616]

431 [366–552]

378 [331–546]

434 [406–667]

500 [405–628]

540 [485–583]

Participants with <50 HIV-1-RNA levels at the time of sampling (n, %)

50 (98%)

18 (100%)

22 (96%)

3 (100%)

4 (100%)

8 (100%)

CD4 cell count (cells/mL), median at 24 weeks [IQR]

511 [336–603]

464 [402–623]

424 [335–528]

638 [507–819]

464 [402–563]

642 [584–669]

Participants with <50 HIV-1-RNA levels at 24 weeks (n, %)

51 (100%)

18 (100%)

23 (100%)

3 (100%)

4 (100%)

8 (100%)

 Tenofovir disoproxil fumarate

26 (51%)

9 (50%)

12 (52%)

2 (67%)

4 (100%)

4 (57%)

 Abacavir sulfate

25 (49%)

9 (50%)

11 (48%)

1 (33%)

0 (0%)

3 (43%)

 Rilpivirine hydrochloride

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

1 (13%)

Duration of DTG treatment (days), median [IQR]

111 [63–169]

112 [78–215]

77 [60–117]

67 [62–111]

67 [44–113]

68 [30–94]

Food consumption

 Fasting

16 (31%)

9 (50%)

8 (35%)

1 (33%)

3 (75%)

5 (63%)

 Light meal

35 (69%)

9 (50%)

15 (65%)

2 (67%)

1 (25%)

3 (37%)

HBV infection (n, %)

4 (8%)

1 (6%)

0 (0%)

0 (0%)

0 (0%)

1 (13%)

HCV infection (n, %)

2 (4%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)